Corcept Therapeutics (NASDAQ:CORT) Insider Sells $325,000.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $65.00, for a total value of $325,000.00. Following the transaction, the insider directly owned 6,230 shares in the company, valued at approximately $404,950. This trade represents a 44.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT traded up $1.11 during mid-day trading on Friday, reaching $69.49. The company had a trading volume of 774,694 shares, compared to its average volume of 1,782,915. The company has a market capitalization of $7.46 billion, a price-to-earnings ratio of 198.55 and a beta of 0.36. The stock has a fifty day moving average of $47.30 and a two-hundred day moving average of $52.18. Corcept Therapeutics Incorporated has a 12-month low of $28.66 and a 12-month high of $91.00.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.19). The company had revenue of $164.90 million for the quarter, compared to analysts’ expectations of $185.83 million. Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.17 earnings per share. Sell-side analysts forecast that Corcept Therapeutics Incorporated will post 0.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Corcept Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CORT. Royal Bank of Canada raised its holdings in Corcept Therapeutics by 18.9% during the first quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock valued at $1,757,000 after buying an additional 2,444 shares in the last quarter. Amundi bought a new stake in shares of Corcept Therapeutics during the 1st quarter worth about $450,000. NewEdge Advisors LLC acquired a new position in shares of Corcept Therapeutics during the 1st quarter valued at about $518,000. EverSource Wealth Advisors LLC increased its holdings in shares of Corcept Therapeutics by 273.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,441 shares of the biotechnology company’s stock valued at $106,000 after acquiring an additional 1,055 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in shares of Corcept Therapeutics by 795.3% in the 2nd quarter. Marshall Wace LLP now owns 46,200 shares of the biotechnology company’s stock valued at $3,391,000 after acquiring an additional 41,040 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord Genuity raised its price target on Corcept Therapeutics to $135 from $110 and reiterated a buy rating, signaling greater confidence in upside potential. Canaccord Genuity price target update
• Positive Sentiment: HC Wainwright lifted its 2026 earnings estimates for CORT, including higher Q3, Q4, and full-year EPS forecasts, while maintaining a buy rating and $95 target. Higher profit expectations often support the stock. HC Wainwright estimate revisions
• Positive Sentiment: Corcept said it plans to resubmit the NDA for relacorilant in Cushing’s syndrome, which keeps a key pipeline asset alive and appears to be the main business-specific catalyst behind the recent rally. Relacorilant NDA resubmission article
• Neutral Sentiment: Stockholders approved an expanded incentive plan and board-related matters at the 2026 annual meeting; this is supportive of governance but not a major immediate earnings driver. Stockholders approve expanded incentive plan and board

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $110.00 to $135.00 and gave the company a “buy” rating in a report on Thursday. UBS Group set a $135.00 price objective on Corcept Therapeutics in a research report on Thursday. Zacks Research raised Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. Wolfe Research raised Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday, March 26th. Finally, Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $88.83.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.